October 12th, 2021 photonamic GmbH & Co. KG (Head office: Pinneberg, Germany; CEO: Ulrich Kosciessa, Ph.D.) (“photonamic”), a subsidiary of SBI Holdings, Inc. (Head office: Tokyo, Japan; Representative Director, President and CEO: Yoshitaka Kitao) and a leader in the pharmaceutical development, translation and global commercialization of 5aminolevulinic acid (“5-ALA”) (*1) today announces that results of an investigatorinitiated proof-of-concept study conducted by St. Olavs Hospital, Trondheim University Hospital (Trondheim, Norway) with a drug support from photonamic to evaluate treatment safety and tolerability of Extracorporeal Photopheresis (ECP) (*2) with 5-ALA in patients with chronic graft-versus-host disease (cGvHD) were published in “Pharmaceutics” on September 26th 2021. ....more
“We are pleased to achieve this impor-tant milestone to our exploration to help patients diagnosed with glioblastoma” explains Ulrich Kosciessa, photonamic GmbH & Co. KG’sCEO. “The accumu-
lation of the fluorescent photosensitizer protoporphyrin IX (PpIX) after systemic administration of 5-ALA proved high tumor selectivity.
Präziser operieren – mit Hilfe aus Pinneberg. Medizinforschung: Erleichterungen für Brustkrebspatientinnen greifbar nahe / Blaues Licht macht Tumorgewebe sichtbar.
“We are pleased having accomplished another milestone in our development for breastcancer program” explains Ulrich Kosciessa, photonamic GmbH & Co. KG’s CEO. “This study played a role in our strategic acquisition of the imaging technology in 2019...